[Form 4] Revolution Medicines, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider sale to cover taxes: This Form 4 shows Jeff Cislini, General Counsel of Revolution Medicines, executed a sale of 1,869 shares of common stock on 09/16/2025 at $45.8249 per share under a Rule 10b5-1 plan adopted May 31, 2023 to satisfy tax withholding for vested restricted stock units (RSUs). After the transaction he beneficially owns 52,224 shares, which includes 43,910 RSUs. The filing was signed by an attorney-in-fact on 09/18/2025. The disclosure is a routine insider tax-withholding sale rather than a discretionary trade.

Positive

• Transaction executed under a Rule 10b5-1 plan, indicating preplanned, non-discretionary sale
• Clear disclosure of post-transaction beneficial ownership (52,224 shares) and RSU amount (43,910 RSUs)
• Sale size is small relative to total beneficial holdings, suggesting administrative tax withholding rather than major divestiture
• Form signed by attorney-in-fact, showing proper execution of filing

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine, pre-arranged sale under a 10b5-1 plan to satisfy tax withholding; not a signal of strategic disposition.

The reported sale of 1,869 shares at $45.8249 was executed under a Rule 10b5-1 instruction adopted May 31, 2023 to cover tax obligations from RSU vesting. The magnitude of the sale is small relative to total shares beneficially owned (52,224) and the large component of unvested/vested RSUs (43,910), indicating the transaction is administrative rather than a liquidity-driven or company-specific signal. For investors, this reduces concerns that an executive is materially divesting ownership for non-tax reasons.

Corporate Governance Expert

TL;DR: Proper use of a 10b5-1 plan and attorney-in-fact signature; disclosure appears compliant and routine.

The filing specifies a 10b5-1 instruction date and shows an attorney-in-fact signature, consistent with governance best practices for preplanned trades and delegation. The inclusion of RSU counts and post-transaction beneficial ownership provides clear transparency. There is no indication of unusual timing or omission of required details in the provided form text.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Cislini Jeff

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2025		S(1)		1,869	D	$45.8249	52,224(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023.

2. Includes 43,910 restricted stock units.

	/s/ Jack Anders, as Attorney-in-fact for Jeff Cislini	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Jeff Cislini sell according to the Form 4 for RVMDW?

He sold 1,869 shares of common stock on 09/16/2025 at $45.8249 per share.

Why was the sale executed under a Rule 10b5-1 plan?

The sale was made pursuant to a Rule 10b5-1 instruction adopted on May 31, 2023 to satisfy the reporting person’s tax withholding obligation related to RSU vesting.

How many shares does the reporting person beneficially own after the transaction?

The filing reports 52,224 shares beneficially owned following the transaction, which includes 43,910 RSUs.

Who signed the Form 4 and when was it filed?

The form bears the signature of Jack Anders, as Attorney-in-fact for Jeff Cislini, dated 09/18/2025.

Does this Form 4 indicate a discretionary insider sale or routine tax withholding?

The Form 4 states the sale was pursuant to a pre-existing 10b5-1 plan to satisfy tax withholding, indicating a routine administrative sale rather than a discretionary divestiture.